Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

57.94 +1.95 (+3.47%)

Streaming Delayed Price Updated: 2:42 PM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

Bristol Myers Q4 Earnings Preview: Profits Under Pressure Even As Wall Street Bets On 2026 Pipeline ↗

Today 3:24 EST

The drugmaker is relying on its newer pipeline to offset Eliquis' upcoming patent cliff in 2028.

Via Stocktwits

Bristol-Myers Squibb Earnings: What To Look For From BMY

February 03, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what to expect.

Via StockStory

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

Bristol-Myers Squibb Co (NYSE:BMY) Shows Strong Technical Setup for Potential Breakout ↗

January 28, 2026

Via Chartmill

Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth ↗

January 17, 2026

Via Chartmill

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year ↗

January 30, 2026

All three can provide you with solid, consistent income.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property World Trade

3 Unpopular Stocks That Concern Us

January 28, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Via The Motley Fool

Topics ETFs Intellectual Property World Trade

AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. ↗

January 23, 2026

Artificial intelligence may be all the rage in the technology sector, but it's also having a huge impact on healthcare.

Via The Motley Fool

Topics Artificial Intelligence

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

January 23, 2026

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

Via The Motley Fool

Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth

January 22, 2026

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...

Via MarketMinute

Topics Earnings Economy Intellectual Property

The Best Stocks to Invest $1,000 in Right Now ↗

January 21, 2026

Large, well-run dividend-paying companies with attractive yields are out there if you look hard enough.

Via The Motley Fool

Topics Intellectual Property

2 Dividend Stocks to Buy and Hold For 10 Years ↗

January 19, 2026

They are unlikely to resort to dividend cuts anytime soon.

Via The Motley Fool

Topics Intellectual Property

2 Buffett Stocks to Load Up On—And 1 to Ditch ↗

January 19, 2026

Via MarketBeat

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Via MarketMinute

Topics Economy Intellectual Property

Thursday's session: gap up and gap down stock in the S&P500 index ↗

January 15, 2026

Via Chartmill

3 Value Stocks That Fall Short

January 14, 2026

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

3 S&P 500 Stocks Walking a Fine Line

January 13, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Via StockStory

Topics Stocks

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance

January 12, 2026

The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

Via MarketMinute

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Via The Motley Fool

Discover which S&P500 stocks are making waves on Wednesday. ↗

January 07, 2026

Via Chartmill

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

Topics Economy Intellectual Property World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.